APA (7th ed.) Citation

R, K., A, L., A, O., A, R., A, G., S, C., . . . L, M. (2024). PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. British journal of cancer, 131(5), 820. https://doi.org/10.1038/s41416-024-02776-7

Chicago Style (17th ed.) Citation

R, Kristeleit, et al. "PARP Inhibition with Rucaparib Alone Followed by Combination with Atezolizumab: Phase Ib COUPLET Clinical Study in Advanced Gynaecological and Triple-negative Breast Cancers." British Journal of Cancer 131, no. 5 (2024): 820. https://doi.org/10.1038/s41416-024-02776-7.

MLA (9th ed.) Citation

R, Kristeleit, et al. "PARP Inhibition with Rucaparib Alone Followed by Combination with Atezolizumab: Phase Ib COUPLET Clinical Study in Advanced Gynaecological and Triple-negative Breast Cancers." British Journal of Cancer, vol. 131, no. 5, 2024, p. 820, https://doi.org/10.1038/s41416-024-02776-7.